{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=4", "query": { "intervention": "High Dose Drug B", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 266, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T18:17:27.022Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06404086", "title": "RECOVER-SLEEP: Platform Protocol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long COVID-19", "Hypersomnia", "Sleep Disturbance" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Modafinil Placebo", "type": "DRUG" }, { "name": "Solriamfetol", "type": "DRUG" }, { "name": "Solriamfetol Placebo", "type": "DRUG" }, { "name": "Melatonin", "type": "DRUG" }, { "name": "Melantonin Placebo", "type": "DRUG" }, { "name": "Tailored lighting (TL) Active", "type": "DEVICE" }, { "name": "Tailored lighting (TL) Placebo", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2024-07-31", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06404086" }, { "nct_id": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "CC-122", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 47, "start_date": "2015-07-27", "completion_date": "2020-07-07", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 8, "location_summary": "La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02406742" }, { "nct_id": "NCT07226362", "title": "A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety, and Tolerability" ], "interventions": [ { "name": "DHE inhalation powder low dose administered via dry powder inhaler (DPI) device", "type": "COMBINATION_PRODUCT" }, { "name": "DHE inhalation powder high dose administered via dry powder inhaler (DPI) device", "type": "COMBINATION_PRODUCT" }, { "name": "DHE injected intravenously (1 mg)", "type": "DRUG" }, { "name": "DHE 2 mg administered by nasal spray (Migranal®)", "type": "DRUG" }, { "name": "Metoclopramide 10mg", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Aspeya Switzerland SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2025-06-09", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226362" }, { "nct_id": "NCT07812805", "title": "SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Selected Advanced Solid Tumors", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Biliary Tract Cancer (BTC)", "Gastric Cancer (GC)", "Esophageal Cancer (EC)", "Head and Neck Squamous Cell Cancer (HNSCC)" ], "interventions": [ { "name": "SKL35501", "type": "DRUG" }, { "name": "SKL35502", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "SK Life Science, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-08-19", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 2, "location_summary": "Glen Burnie, Maryland • Pittsburgh, Pennsylvania", "locations": [ { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07812805" }, { "nct_id": "NCT06305806", "title": "RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long Covid19", "Long Covid-19" ], "interventions": [ { "name": "Ivabradine", "type": "DRUG" }, { "name": "Ivabradine Placebo", "type": "DRUG" }, { "name": "Coordinated Care", "type": "BEHAVIORAL" }, { "name": "Usual Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Kanecia Obie Zimmerman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2024-03-11", "completion_date": "2025-12-17", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06305806" }, { "nct_id": "NCT00704106", "title": "Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "Entecavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pacific Health Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2008-05", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 6, "location_summary": "Palo Alto, California • San Jose, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00704106" }, { "nct_id": "NCT07285668", "title": "Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 38, "start_date": "2026-02-26", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285668" }, { "nct_id": "NCT01993017", "title": "Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Coronary Syndrome", "Depressive Symptoms" ], "interventions": [ { "name": "Cognitive Behavioral Therapy (CBT)", "type": "OTHER" }, { "name": "Antidepressant Medication", "type": "DRUG" }, { "name": "Standard Care", "type": "OTHER" }, { "name": "Depressive symptom screener", "type": "OTHER" }, { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 1501, "start_date": "2013-11", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 4, "location_summary": "Bloomington, Minnesota • New York, New York • Henderson, North Carolina + 1 more", "locations": [ { "city": "Bloomington", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Henderson", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01993017" }, { "nct_id": "NCT00775606", "title": "Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acquired Immune Deficiency Syndrome" ], "interventions": [ { "name": "Lopinavir 400 mg/ritonavir 100 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 15, "start_date": "2008-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 4, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00775606" }, { "nct_id": "NCT06384222", "title": "Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Risk Prostate Carcinoma", "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Hyperpolarized [1-13C] pyruvate (HP 13C)", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "Non-investigational radical prostatectomy (RP)", "type": "PROCEDURE" }, { "name": "Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ivan de Kouchkovsky, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2024-12-09", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-07T18:17:27.022Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06384222" } ] }